Re-evaluating experimental validation in the Big Data Era: a conceptual argument.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay.Molecular & cellular proteomics : MCP · 2026
   Article
2. Informative Missingness in Nominal Data: A Graph-Theoretic Approach to Revealing Hidden Structure.Computational and structural biotechnology journal · 2026
   Article
3. Divergent roles of PKM2 in regulating PD-L1 and PD-L2 expression and their implications in human and mouse cancer models.Acta biochimica et biophysica Sinica · 2025
   Article
4. Integrative multi-omics and systems bioinformatics in translational neuroscience: A data mining perspective.Journal of pharmaceutical analysis · 2023
   Review
5. A New Strategy for the Old Challenge of Thalidomide: Systems Biology Prioritization of Potential Immunomodulatory Drug (IMiD)-Targeted Transcription Factors.International journal of molecular sciences · 2023
   Article
6. Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma.Blood · 2023
   Article
7. Access to ground truth at unconstrained size makes simulated data as indispensable as experimental data for bioinformatics methods development and benchmarking.Bioinformatics (Oxford, England) · 2022
   Article
8. A Novel Machine Learning 13-Gene Signature: Improving Risk Analysis and Survival Prediction for Clear Cell Renal Cell Carcinoma Patients.Cancers · 2022
   Article
9. Bipartite network models to design combination therapies in acute myeloid leukaemia.Nature communications · 2022
   Article
10. Integrating Multimorbidity into a Whole-Body Understanding of Disease Using Spatial Genomics.Results and problems in cell differentiation · 2022
    Article
11. Assessing developability early in the discovery process for novel biologics.mAbs
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as